Abstract
Depressive disorders, are not only common but also among the leading causes of disability worldwide. They are associated with increased incidences of various other diseases. It has been shown that in patients with autoimmune diseases, when depression coexists, the quality of life is worse and medical treatment and management is compromised. Depression-like symptoms, such as fatigue and disinterest are also common in inflammatory rheumatic diseases and often associated with poor quality of life. Medical therapy targeting inflammation results in alleviation of these symptoms in many patients. Interestingly, there is cumulating evidence suggesting potential roles of inflammatory cytokines in the pathogenesis of major depression. Effects of some of the biological agents used in rheumatic diseases have been studied on depressive disorders. Results have been controversial and further studies are needed in this area. These findings suggest associations between depression and inflammatory rheumatic diseases and raise the possibility that treatment of one of them might influence the outcome of the other. We have reviewed the current literature on associations between depression and inflammatory rheumatologic diseases, such as rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and ankylosing spondylitis.
Keywords: Depression, Inflammation, Rheumatic, Rheumatoid arthritis, Systemic lupus erythematosus, Ankylosing spondylitis, Sjögren's syndrome.
Current Topics in Medicinal Chemistry
Title:Associations between Depressive Disorders and Inflammatory Rheumatic Diseases
Volume: 18 Issue: 16
Author(s): Özkan Varan, Hakan Babaoğlu and Berna Göker*
Affiliation:
- Department of Internal Medicine-Rheumatology, Faculty of Medicine, Gazi University, Ankara,Turkey
Keywords: Depression, Inflammation, Rheumatic, Rheumatoid arthritis, Systemic lupus erythematosus, Ankylosing spondylitis, Sjögren's syndrome.
Abstract: Depressive disorders, are not only common but also among the leading causes of disability worldwide. They are associated with increased incidences of various other diseases. It has been shown that in patients with autoimmune diseases, when depression coexists, the quality of life is worse and medical treatment and management is compromised. Depression-like symptoms, such as fatigue and disinterest are also common in inflammatory rheumatic diseases and often associated with poor quality of life. Medical therapy targeting inflammation results in alleviation of these symptoms in many patients. Interestingly, there is cumulating evidence suggesting potential roles of inflammatory cytokines in the pathogenesis of major depression. Effects of some of the biological agents used in rheumatic diseases have been studied on depressive disorders. Results have been controversial and further studies are needed in this area. These findings suggest associations between depression and inflammatory rheumatic diseases and raise the possibility that treatment of one of them might influence the outcome of the other. We have reviewed the current literature on associations between depression and inflammatory rheumatologic diseases, such as rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and ankylosing spondylitis.
Export Options
About this article
Cite this article as:
Varan Özkan, Babaoğlu Hakan and Göker Berna *, Associations between Depressive Disorders and Inflammatory Rheumatic Diseases, Current Topics in Medicinal Chemistry 2018; 18 (16) . https://dx.doi.org/10.2174/1568026618666180516100805
DOI https://dx.doi.org/10.2174/1568026618666180516100805 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Chronic Kidney Disease
The scope of the special thematic issue includes but not limited to the mechanism of chronic kidney disease (CKD), the treatment of renal fibrosis and early diagnosis of CKD and so on. We also welcome manuscripts from other scientific research area with respect to internal medicine. Cell death has been ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Screening of SLE-susceptible SNPs in One Chinese Family with Systemic Lupus Erythematosus
Current Bioinformatics Traditional Chinese Medicine for Managing Inflammatory Pain of Arthritis with Herbal Medicines
Current Traditional Medicine Recent Patents Therapeutic Agents for Cancer
Recent Patents on Anti-Cancer Drug Discovery Management of Connective Tissue Interstitial Lung Disease
Current Respiratory Medicine Reviews Mimicking Self-Antigens with Synthetic Peptides in Systemic Autoimmune Rheumatic Diseases
Current Clinical Pharmacology Discovery of Structural Prospects of Imidazo[1,5-a]pyrazine Derivatives as BTK Inhibitors Against Cancer: A Computational Study
Letters in Drug Design & Discovery MicroRNAs and their Implications in CD4+ T-cells, Oligodendrocytes and Dendritic Cells in Multiple Sclerosis Pathogenesis
Current Molecular Medicine Curcumin and its Derivatives Targeting Multiple Signaling Pathways to Elicit Anticancer Activity: A Comprehensive Perspective
Current Medicinal Chemistry Alkannins and Shikonins: A New Class of Wound Healing Agents
Current Medicinal Chemistry Editorial: The Explosion of Biosimilars in Immune Mediated Chronic Inflammatory Diseases
Current Pharmaceutical Design Evidence on the Protective Role of High-Density Lipoprotein (HDL) in HIV-Infected Individuals
Current Vascular Pharmacology Xenobiotic Sulphation and its Variability During Inflammation: a Factor in Adverse Drug Reactions?
Current Drug Metabolism Novel Aspects in the Pathogenesis of Nonalcoholic Steatohepatitis
Current Molecular Medicine The Molecular Targets of Cannabinoids in the Treatment of Cancer and Inflammation
Current Pharmaceutical Design New Potential Serum Biomarkers in Multiple Sclerosis Identified by Proteomic Strategies
Current Medicinal Chemistry A Review on the Risk of Myocardial Infarction Associated with the NSAID Diclofenac
Cardiovascular & Hematological Disorders-Drug Targets Editorial [Hot topic: General Aspects of Biologic Agents in Rheumatology (Guest Editor: Omer Faruk Sendur)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Antisense Therapy for Cardiovascular Diseases
Current Pharmaceutical Design The Mast Cell Pathway to Inflammation and Homeostasis: Pharmacolo- gical Insights
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Hydrogen Sulfide-Based Therapies: Focus on H2S Releasing NSAIDs
Inflammation & Allergy - Drug Targets (Discontinued)